Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Iontas

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SARS-CoV2 neutralizing antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: FairJourney Biologics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            The newly-identified panel of antibodies have been shown to block infection at doses as low as 20pM in pseudoviral assays and 100pM in live coronavirus assays, surpassing or matching the best antibodies reported.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Inotrem

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 07, 2020

            Details:

            As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: FairJourney Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 16, 2020

            Details:

            The combination will enable the newly created partnership to isolate highly specific, neutralizing SARS-CoV-2 antibodies displaying high affinity and preferential biophysical characteristics.